
Akari Therapeutics (AKTX) Stock Forecast & Price Target
Akari Therapeutics (AKTX) Analyst Ratings
Bulls say
Akari Therapeutics PLC is developing AKTX-101, a preclinical stage Trop2-targeting antibody-drug conjugate (ADC) that has shown promising preclinical efficacy against bladder and gastric cancers, particularly in combination with immuno-oncology agents. The preclinical data suggests that AKTX-101 not only demonstrates significant anti-tumor activity but also potentially generates immunological memory, enhancing long-term protection against tumor rechallenge. The novel ADC platform may lead to best-in-class therapeutic outcomes, especially when integrated with existing immunotherapies, which positions Akari favorably within the oncology landscape.
Bears say
Akari Therapeutics PLC presents a promising ADC platform; however, its weak balance sheet poses a significant risk that could negatively impact investor sentiment. The potential financial overhang is expected to weigh on the stock, particularly as the company seeks to secure additional funding for its ongoing and planned preclinical and clinical programs. Until such funding is obtained, continued concerns regarding financial stability may hinder the company's stock performance.
This aggregate rating is based on analysts' research of Akari Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Akari Therapeutics (AKTX) Analyst Forecast & Price Prediction
Start investing in Akari Therapeutics (AKTX)
Order type
Buy in
Order amount
Est. shares
0 shares